Dr Robert A Blake

Robert A. Blake (DPhil) is a senior principal scientist in the department of Biochemical and Cellular Pharmacology at Genentech (previously at Sugen, Exelixis, and iPierian). He pioneered the concepts around monovalent protein degraders through the discovery of the selective BRD4 monovalent degrader GNE-0011 and recently published on various strategies of induced protein degradation and novel target engagement methods. He has previously published on selective inhibitors of: HSP90, protein kinases, tankyrase and deubiquitinases; and on high content fluorescence imaging-based methods. He was a member of the team that developed the angiogenesis inhibitor SUTENT (SU11248) and the team that developed the selective estrogen receptor degrader (SERD) GDC-9545 (Giredestrant). His current focus is the development of drugs that act through modulating target protein homeostasis, particularly protein degradation.